Table 3 MR Imaging features of iCCA
Imaging features | Subtype | ||
|---|---|---|---|
Small duct type (n = 63) | Large duct type (n = 30) | p value | |
Intratumoral hemorrhage a | 2 (3.2%) | 2 (6.7%) | 0.438 |
Targetoid restriction | 31 (49.2%) | 4 (13.3%) | 0.001* |
Restricted diffusion | 63 (100%) | 32 (100%) | > 0.999 |
Arterial enhancement pattern | |||
Arterial phase hypoenhancement | 3 (4.8%) | 9 (30%) | 0.001 |
Rim APHE | 48 (76.2%) | 17 (56.7%) | 0.055 |
Non-rim APHE | 12 (19.0%) | 4 (13.3%) | 0.495 |
T2-weighted signal intensity | |||
Diffused iso- / mild-hyperintense | 20 (31.7%) | 15 (50.0%) | 0.089 |
Diffused marked hyperintense | 19 (30.2%) | 13 (43.3%) | 0.211 |
Targetoid appearance in T2 | 24 (38.1%) | 2 (6.7%) | 0.002* |
Peripheral washout | 19 (30.2%) | 4 (13.3%) | 0.079 |
Non-peripheral washout a | 5 (7.9%) | 1 (3.3%) | 0.372 |
Delayed enhancement | 54 (85.7%) | 26 (86.7%) | 0.901 |
Corona enhancement | 25 (39.7%) | 8 (26.7%) | 0.220 |
Enhancing capsule a | 8 (12.7%) | 3 (10.0%) | 0.706 |
Tumor in vein a | 4 (6.3%) | 7 (23.3%) | 0.018* |
Intrahepatic duct dilatation | 11 (17.5%) | 23 (76.7%) | < 0.001* |
Hepatic capsule retraction | 29 (46.0%) | 11 (36.7%) | 0.394 |